On November 21, 2018 Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, reported that Michele Garufi, Chairman and Chief Executive Officer of Nicox, will present at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday November 27, 2018 at 11:30 am ET (Press release, NicOx, NOV 21, 2018, View Source [SID1234531573]). The conference is being held at the Lotte New York Palace in New York.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on Nicox website (www.nicox.com) in the "Presentations & Events" section. A replay of the webcast will be also archived.

Mr Garufi will be available for one-on-one meetings at the conference

On November 21, 2018 Amgen (NASDAQ: AMGN) reported that it will present at the Piper Jaffray Healthcare Conference at 8:30 a.m. ET on Tuesday, Nov. 27, 2018, in New York City and at the Evercore ISI Healthcare Conference at 11 a.m. ET on Wednesday, Nov. 28, 2018, in Boston (Press release, Amgen, NOV 21, 2018, View Source [SID1234531552]). Elliott M. Levy, M.D., senior vice president of Global Development at Amgen, will present at the conferences. Live audio of each presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. A replay of each webcast will also be available on Amgen’s website for at least 90 days following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 20, 2018 Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, reported that John G. Houston, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27 at 8:00 a.m. ET in New York City (Press release, Arvinas, NOV 20, 2018, View Source [SID1234531495]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available at www.arvinas.com on the Events page. A replay of the webcast will be archived on the Arvinas website for 30 days following the presentation.

On November 20, 2018 Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, reported that Aron Knickerbocker, Chief Executive Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference, November 28, 2018 at 11:10 am ET (Press release, Five Prime Therapeutics, NOV 20, 2018, View Source [SID1234531513]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast and may be accessed at the "Events & Presentations" section of the Company’s website at View Source Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.

On November 20, 2018 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), reported that it will participate in the following investor conferences (Press release, Akebia, NOV 20, 2018, View Source [SID1234531537]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 30th Annual Piper Jaffray Healthcare Conference onWednesday, November 28, 2018, at 12:30 p.m. Eastern Time at the Lotte New York Palace Hotel. Akebia will participate in a fireside chat discussion; and
The Global Mizuho Investor Conference on Monday, December 3, 2018, at the Lotte New York Palace Hotel.
A replay of the webcast from the Piper Jaffray Healthcare Conference will be available on the company’s website at www.akebia.com the day following the conference. To access, please log onto the Akebia website at least 15 minutes prior to the webcast to ensure adequate time for any software downloads that may be required.